RecruitingNot applicableNCT06618313
One Trial to Evaluate the Safety, Tolerability and Efficacy of JCXH-213 in Patients With r/r B-NHL
Studying Non-Hodgkin lymphoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Beijing GoBroad Hospital
- Principal Investigator
- Kai Hu, Chief PhysicianBeijing GoBroad Hospital
- Intervention
- JCXH-213,an mRNA-LNP based in vivo CAR therapy(drug)
- Enrollment
- 8 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2025 – 2026
Study locations (1)
- Department of Lymphoma and Myeloma, Yuhengnan Road, Changping District, Beijing, Beijing, China
Collaborators
Ruijin Hospital
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06618313 on ClinicalTrials.govOther trials for Non-Hodgkin lymphoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT07222631SB-4826 in Adult Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin LymphomasUniversity of California, San Diego
- RECRUITINGNCT07313943PAX5-NEGATIVE HODGKIN-LIKE LYMPHOMAS: A DIAGNOSTIC CHALLANGEIRCCS Azienda Ospedaliero-Universitaria di Bologna
- RECRUITINGPHASE1NCT07284927Clinical Study of LV009 Injection for the Treatment of Hematologic and Lymphoid MalignanciesPersonGen BioTherapeutics (Suzhou) Co., Ltd.
- RECRUITINGPHASE2NCT07283822Amping up With PemJAKSeda S. Tolu
- RECRUITINGPHASE2NCT07285590Clinical Trial to Evaluate the Efficacy and Safety of Pirtobrutinib With Rituximab in Patients With Mantle Cell LymphomaGrupo Español de Linfomas y Transplante Autólogo de Médula Ósea
- RECRUITINGPHASE1NCT07283796A Study to Assess PK, Safety and Efficacy of HSK47977 Tablets in Subjects With Relapsed or Refractory Non-Hodgkin's LymphomaHaisco Pharmaceutical Group Co., Ltd.
- RECRUITINGPHASE1, PHASE2NCT06838832Novel Allogenic CD19-targeting CAR-γδT Cell Therapy (QH103E) in r/r NHLChinese PLA General Hospital
- RECRUITINGNANCT06923397Interrupting Sedentary Time to Improve Cardiometabolic Health and Toxicity in Patients With Lymphoma Receiving Chemotherapy: The iSTAND TrialDana-Farber Cancer Institute